BGC
EPRX

Beutel, Goodman & Co’s Eupraxia Pharmaceuticals EPRX Stock Holding History

Beutel, Goodman & Co’s Portfolio EPRX Stock Details EPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$23.8M Sell
3,627,864
-38,601
-1% -$266K 0.18% 64
2026
Q1 		$26.4M Sell
3,666,465
-42,908
-1% -$345K 0.18% 62
2025
Q4 		$27.9M Sell
3,709,373
-349,526
-9% -$2.15M 0.17% 56
2025
Q3 		$23.9M Buy
+4,058,899
New +$22.1M 0.14% 56

Other funds holding EPRX

AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
SC
Scotia Capital Toronto, Ontario, Canada $26.8B AUM 33.07% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Beutel, Goodman & Co's EPRX Position: Q2 2026 in Review

Beutel, Goodman & Co reduced its Eupraxia Pharmaceuticals (EPRX) stake by 1.1% in Q2 2026, selling an estimated $266K and leaving 3,627,864 shares worth $23.8M. The position accounts for 0.18% of the portfolio, ranked #64.

Beutel, Goodman & Co first reported a position in EPRX in Q3 2025 and has held it in 4 quarters since. The position peaked at $27.9M in Q4 2025. 68 funds tracked by Wall St. Rank hold EPRX as of Q2 2026.

  • Beutel, Goodman & Co held 3,627,864 shares of Eupraxia Pharmaceuticals worth $23.8M as of Q2 2026.
  • Beutel, Goodman & Co sold 38,601 Eupraxia Pharmaceuticals shares in Q2 2026, an estimated $266K.
  • Eupraxia Pharmaceuticals made up 0.18% of Beutel, Goodman & Co's portfolio in Q2 2026, its #64 holding.
  • Beutel, Goodman & Co first reported a position in Eupraxia Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • Beutel, Goodman & Co's Eupraxia Pharmaceuticals position peaked at $27.9M in Q4 2025.
  • 68 funds tracked by Wall St. Rank held Eupraxia Pharmaceuticals as of Q2 2026.

Based on Beutel, Goodman & Co's 13F filing for Q2 2026, filed 12 Aug 2026.